Aide Brito-Nadjmabadi, PA-C

Aide Brito-Nadjmabadi practices at Dignity Health - Mercy Hospital Downtown in Bakersfield, California, part of CommonSpirit Health.

Aide Brito-Nadjmabadi's NPI, 1477852424, was assigned on March 16, 2011. Aide Brito-Nadjmabadi holds California license PA21479.

Aide Brito-Nadjmabadi's primary practice is Dignity Health - Mercy Hospital Downtown, at 2215 Truxtun Avenue, Bakersfield, CA 93301 in Kern County. The practice phone is (661) 632-5000.

Aide Brito-Nadjmabadi's primary practice is Dignity Health - Mercy Hospital Downtown in Bakersfield, California, part of CommonSpirit Health. The medical group on file is Vituity. Dmand AI also links Aide Brito-Nadjmabadi to 2 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Aide Brito-Nadjmabadi practices. Vendor and product names are available with a free account.

Medical is Aide Brito-Nadjmabadi's primary specialty in the NPI Registry, under taxonomy code 363AM0700X. Aide Brito-Nadjmabadi is board certified in certified physician assistant by the National Commission on Certification of Physician Assistants (NCCPA). Aide Brito-Nadjmabadi is licensed in California.

CMS data shows 157 Medicare services from Aide Brito-Nadjmabadi across 4 procedure codes in 2024, for 144 Medicare patients. Medicare paid $12,264 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 144 Medicare patients who saw Aide Brito-Nadjmabadi in 2024. The largest group is 65 to 74, with 59 patients. 72% of them have high blood pressure, and 70% have high cholesterol. 59% are also on Medicaid. Their average risk score is 1.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Aide Brito-Nadjmabadi's median patient age at 31, with 60% women.

In 2024, Aide Brito-Nadjmabadi wrote 144 Medicare Part D claims for 108 patients. 96% of them were for generic drugs. CMS names the drug for 43 of them, across 3 drugs with 11 or more claims each, at $2,384 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Aide Brito-Nadjmabadi for performance year 2024, reported as part of a group.

CMS Open Payments shows 8 general payments to Aide Brito-Nadjmabadi from 3 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Novo Nordisk Inc paid the most, $105.

Aide Brito-Nadjmabadi is a member of AAPA.